Taken together, our data shed light on an unexpected role of the TAp63α/IKKβ/ER stress pathway in liver disease and identify p63 as a putative therapeutic target to tackle NAFLD. This evidence concerns the gene IKBKB and metabolic dysfunction-associated steatotic liver disease.